Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temocillin PK/PD in ESRD Patients on Hemodialysis
NCT02285075Phase 4Completed
- Sponsor
- AZ Sint-Jan Brugge
- Start
- Jun 2011
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of temocillin in Gram-negative bacterial infection, sponsored by AZ Sint-Jan Brugge. Primary endpoints: Percentage of the dosing interval time above a Minimum Inhibitory Concentration of 8 mg/L and Percentage of the dosing interval time above a Minimum Inhibitory Concentration of 16 mg/L. Started Jun 2011; status: completed.
02
Drugs
temocillin
03
Conditions
Gram-negative bacterial infection
Beyond the preview
Go deeper on NCT02285075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02285075.